TY - JOUR
T1 - Carotid artery intima-media thickness and HIV infection
T2 - Traditional risk factors overshadow impact of protease inhibitor exposure
AU - Currier, Judith S.
AU - Kendall, Michelle A.
AU - Zackin, Robert
AU - Henry, W. Keith
AU - Alston-Smith, Beverly
AU - Torriani, Francesca J.
AU - Schouten, Jeff
AU - Mickelberg, Keith
AU - Li, Yanjie
AU - Hodis, Howard N.
PY - 2005/6/10
Y1 - 2005/6/10
N2 - Context: The impact of HIV infection and exposure to antiretroviral therapy on the development of subclinical atherosclerosis is incompletely understood. Objective: To compare intima-media thickness (IMT) of the carotid artery between HIV-infected subjects receiving protease inhibitor-containing regimens and subjects not receiving these regimens and to compare differences in the IMT of the carotid artery between HIV-infected subjects and HIV-uninfected subjects. Methods: A prospective matched cohort study in university-based outpatient clinics. Groups of three individuals (triads) matched on the following characteristics were enrolled: age, sex, race/ethnicity, smoking status, blood pressure and menopausal status. Group 1, HIV-infected subjects with continuous use of protease inhibitor (PI) therapy for ≥ 2 years; group 2, HIV-infected subjects without prior PI use; and group 3: HIV-uninfected. Ultrasonographers at six sites sent standardized ultrasound images to a central reading site for carotid IMT measurements. Carotid IMT was compared within the HIV-infected groups (1 and 2) and between the HIV-infected and uninfected groups in a matched analysis. Results: One hundred and thirty-four individuals were enrolled in 45 triads. The median IMT in groups 1, 2 and 3 was 0.690, 0.712 and 0.698 mm, respectively. There were no statistically significant differences in IMT between groups 1 and 2, or in the combined HIV groups compared with the HIV uninfected group. Significant predictors of carotid IMT in a multivariate model included high-density lipoprotein (HDL) cholesterol, the interaction of HDL cholesterol and triglycerides, age and body mass index. Conclusions: We found no association between PI inhibitor exposure or HIV infection and carotid IMT.
AB - Context: The impact of HIV infection and exposure to antiretroviral therapy on the development of subclinical atherosclerosis is incompletely understood. Objective: To compare intima-media thickness (IMT) of the carotid artery between HIV-infected subjects receiving protease inhibitor-containing regimens and subjects not receiving these regimens and to compare differences in the IMT of the carotid artery between HIV-infected subjects and HIV-uninfected subjects. Methods: A prospective matched cohort study in university-based outpatient clinics. Groups of three individuals (triads) matched on the following characteristics were enrolled: age, sex, race/ethnicity, smoking status, blood pressure and menopausal status. Group 1, HIV-infected subjects with continuous use of protease inhibitor (PI) therapy for ≥ 2 years; group 2, HIV-infected subjects without prior PI use; and group 3: HIV-uninfected. Ultrasonographers at six sites sent standardized ultrasound images to a central reading site for carotid IMT measurements. Carotid IMT was compared within the HIV-infected groups (1 and 2) and between the HIV-infected and uninfected groups in a matched analysis. Results: One hundred and thirty-four individuals were enrolled in 45 triads. The median IMT in groups 1, 2 and 3 was 0.690, 0.712 and 0.698 mm, respectively. There were no statistically significant differences in IMT between groups 1 and 2, or in the combined HIV groups compared with the HIV uninfected group. Significant predictors of carotid IMT in a multivariate model included high-density lipoprotein (HDL) cholesterol, the interaction of HDL cholesterol and triglycerides, age and body mass index. Conclusions: We found no association between PI inhibitor exposure or HIV infection and carotid IMT.
UR - http://www.scopus.com/inward/record.url?scp=20644459485&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20644459485&partnerID=8YFLogxK
U2 - 10.1097/01.aids.0000171406.53737.f9
DO - 10.1097/01.aids.0000171406.53737.f9
M3 - Article
C2 - 15905673
AN - SCOPUS:20644459485
SN - 0269-9370
VL - 19
SP - 927
EP - 933
JO - AIDS
JF - AIDS
IS - 9
ER -